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Abstract: Estrogen (E2) is a major risk factor for the initiation and progression of malignancy in
estrogen receptor (ER) positive breast cancers, whereas sirtuin 3 (Sirt3), a major mitochondrial
NAD+-dependent deacetylase, has the inhibitory effect on the tumorigenic properties of ER positive
MCF-7 breast cancer cells. Since it is unclear if this effect is mediated through the estrogen receptor
alpha (ERα) signaling pathway, in this study, we aimed to determine if the tumor-suppressive function
of Sirt3 in MCF-7 cells interferes with their response to E2. Although we found that Sirt3 improves the
antioxidative response and mitochondrial fitness of the MCF-7 cells, it also increases DNA damage
along with p53, AIF, and ERα expression. Moreover, Sirt3 desensitizes cells to the proliferative
effect of E2, affects p53 by disruption of the ERα–p53 interaction, and decreases proliferation, colony
formation, and migration of the cells. Our observations indicate that these tumor-suppressive effects
of Sirt3 could be reversed by E2 treatment only to a limited extent which is not sufficient to recover
the tumorigenic properties of the MCF-7 cells. This study provides new and interesting insights with
respect to the functional role of Sirt3 in the E2-dependent breast cancers.
Keywords: sirtuin 3; MCF-7; estrogen receptor; p53; breast cancer cells
1. Introduction
17β-estradiol (E2) is a steroid hormone essential for the maintenance of the female reproductive
system with important physiological functions in the immune, cardiovascular, and neural systems [1,2].
However, E2 is a major risk factor for initiation and progression of malignancy in estrogen receptor
(ER) positive breast cancers [3]. E2 mainly exerts its effect through the classical genomic pathway
involving estrogen receptors alpha (ERα) and beta (ERβ) that function as transcription factors [4], with
ERα being essential for proliferative signaling in both normal and breast cancer cells [5]. By binding
to ERα, E2 promotes cellular proliferation through the upregulation of cell cycle regulating genes,
and simultaneously triggers ERα proteasomal degradation required for the cellular response to
environmental E2 levels [6].
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Sirtuin 3 (Sirt3), NAD+ dependent deacetylase, is the only member of the sirtuin family that is
linked to longevity in humans. In addition, important cellular and mitochondrial processes, including
reactive oxygen species (ROS) generation, are integrated through Sirt3. It has been shown that Sirt3
has a bifunctional role in cancer, acting as both oncoprotein and tumor suppressor, depending on
the tissue and cancer-type specific metabolic programs [7]. We have recently shown that Sirt3 has
the inhibitory effect on tumorigenic properties of ERα positive breast cancer cells, particularly when
combined with hyperoxic treatment [8]. However, it is not clear if this effect is mediated through the
ERα signaling pathway.
While ERα plays an important role in the progression of breast cancer, p53 functions as a major
tumor suppressor through induction of target genes for cell cycle arrest and DNA repair [9]. Given
that p53 functions primarily as a tumor suppressor, any aberration in the p53 gene or dysfunction of
p53-mediated signaling pathway leads to cellular proliferation and potential tumorigenesis [10]. Breast
cancer cells usually have functional p53, although its activity is altered by various mechanisms [11].
In ERα positive breast cancer cells, the abrogation of the p53 signaling pathway is a major event towards
cancer progression, where p53 is functionally repressed by interaction with ERα [12]. However, the
mechanism underlying the inactivation of p53 function is not fully understood.
Although the elevated levels of ERα contribute to an increased risk of breast cancer [3], it has
also been reported that ERα overexpression can be associated with reduced metabolic potential and
invasiveness [13]. Earlier studies have shown that low Sirt3 expression is associated with reduced
survival in all breast cancers and highlighted its potential role as a biomarker to assist in identifying high
risk patients [14]. Furthermore, it was also shown that the full-length nuclear Sirt3 can indirectly activate
and prevent degradation of p53 in MCF-7 cells through deacetylation of phosphatase PTEN [15].
Considering the tumor suppressive role of Sirt3, we hypothesized that E2/ERα signaling can be
negatively affected by Sirt3. So far, it has not been shown that Sirt3 exerts its tumor-suppressive
function in MCF-7 cells by interfering with their response to E2.
Here, we report that overexpressed Sirt3 reduces the response of MCF-7 cells to E2, affects p53 by
disruption of the ERα–p53 interaction, and inhibits the clonogenic growth of MCF-7 cells. Thus, Sirt3
can be considered to reduce tumor-initiating capacity of these cells by attenuating response of the ERα
positive breast cancer cells to the E2. These results provide new and interesting insights concerning the
functional role of Sirt3 in breast cancer and its therapeutic potential in hormone-positive breast tumors.
2. Materials and Methods
2.1. Cell Lines, Transfection, Treatments
The MCF-7 cell line was obtained from Public Health England (London, UK; ECACC 86012803),
tested for mycoplasma contamination, and was grown in high glucose Dulbecco’s modified Eagle
medium (DMEM, Sigma-Aldrich, St. Louis, MO, USA) with 10% fetal bovine serum (FBS, Capricorn
Scientific, Germany), 1% nonessential amino acids (Sigma-Aldrich, St. Louis, MO, USA) and 1%
antibiotic/antimycotic solution (Capricorn Scientific, Germany) at 37 ◦C with 5% CO2 in a humidified
atmosphere. Due to the commercial source of the cells, there was no need to authenticate them prior to
the study. The MCF-7 cells were transfected with the FLAG-tagged Sirt3 (MCF-7S3) or empty pcDNA3.1
plasmid (MCF-7C), as described previously in [8]. To examine the E2 effect on the characteristics
of E2-dependent cell growth, we used white DMEM medium with steroid free (charcoal treated)
serum (Sigma-Aldrich, St. Louis, MO, USA), since it is known that phenol red can activate ERα gene
regulation [16,17]. Therefore, in our study, both phenol red and white DMEM (Capricorn Scientific,
Germany) were used, depending on the parameters examined. For the experiments in white DMEM,
cells were grown in this media for one week before the experiments. In our research, we treated cells
with 10 nM E2 (17β-estradiol, Sigma-Aldrich, St. Louis, MO, USA) for 2 h and if we wanted to confirm
that E2 effect was mediated by ERα, we treated cells with ERα inhibitor 100 nM ICI (ICI 182,780; Santa
Cruz Biotechnology, Dallas, TX, USA) 2 h before adding E2.
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2.2. RNA Isolation, Reverse Transcription, and qPCR Analysis
Total RNA was isolated from ~106 cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Relative gene expression of sirt-3 (Hs00953477_m1,
TaqMan, Thermo Fisher Scientific, Waltham, MA, USA) and esr-1 (Hs01046816_m1, TaqMan, Thermo
Fisher Scientific, Waltham, MA, USA) were quantified by reverse transcription of total RNA and
real-time quantitative PCR (qPCR) analysis. Data were analyzed using the 2−∆∆Ct method and
presented as the fold change in gene expression normalized to endogenous reference gene (β-actin;
Hs01060665_g1, TaqMan, Thermo Fisher Scientific, Waltham, MA, USA) and relative to the control.
All reactions were carried out in triplicate.
2.3. siRNA-Mediated Silencing of Sirt3 and ERα Expression
Silencing of Sirt3 and ERα expression was done using Lipofectamine2000 (Thermo Fisher Scientific,
Waltham, MA, USA) according to the manufacturer’s guidelines. Sirt3 siRNA (siSirt3), ERα siRNA
(siERα), and scrambled control siRNA (siSCR) were obtained from Ambion (Thermo Fisher Scientific,
Waltham, MA, USA). Cells (105) were seeded on a 24-well plate, and 24 h later transfected with 100 nM
siRNA for 48 h, followed by protein collection and Western blot analysis for targeted proteins.
2.4. Fractionation, SDS-PAGE, and Western Blot Analysis
For fractionation analysis, 2 × 106 cells were seeded on 10 cm Petri dish and 24 h later treated
with ICI and E2, followed by fractionation by Cell Fractionation Kit Standard (ab109719, Abcam,
UK) according to the manufacturer’s instructions. Proteins of obtained fractions were measured by
Pierce™ BCA Protein Assay Kit (Thermo Fischer Scientific, Waltham, MA, USA) and prepared in
SDS-PAGE sample buffer (100 mM Tris-HCl (pH 6,8), 2% SDS, 20% glycerol, 4% β-mercaptoethanol,
0.5% bromophenol blue dye) for Western blot analysis. Anti-GAPDH and anti-H3 antibodies were
used as controls for purity of cytoplasmic and nuclear fractions, respectively [18,19]. Total cellular
proteins for Western blot analysis were isolated in Ripa buffer with protease inhibitors (Roche, Basel,
Switzerland). SDS-PAGE and Western blot analysis were carried out as described previously in [8].
Primary and secondary antibodies used in this study are listed in Supplementary Table S1.
2.5. Immunofluorescence, Micronucleated Cells and Confocal Microscopy
Immunofluorescence analysis was performed as described previously in [20]. When MitoTracker
Deep Red (Thermo Fisher Scientific, Waltham, MA, USA) was used, cells were labelled with 100 nM
MitoTracker for 20 minutes before the end of the E2 treatment. Primary and secondary antibodies used
in this study are listed in Supplementary Table S2. DAPI (4,6-diamidino-2-fenilindol, Sigma-Aldrich,
St. Louis, MO, USA) was used for nuclear staining. For detection of micronucleated cells, 104 cells/well
were seeded on coverslips in a 24-well plate and were grown in white DMEM for 10 days, then fixed
with 4% PFA, and stained with 5 µM Hoechst 33342 (Sigma-Aldrich, St. Louis, MO, USA) for 10 min.
As a positive control, formation of micronucleated cells in MCF-7C clone was induced with 400 µM
H2O2 for 4 h after which they were left to grow in fresh DMEM for the next 72 h, and then were further
processed and analyzed as untreated cells. Confocal imaging was performed by sequential scanning
using a Leica TCS SP8 X laser scanning microscope (Leica Microsystems, Germany), equipped with a
HC PL APO CS2 63/1.40 oil immersion objective and a white light laser. The excitation wavelengths
and emission detection ranges used were 350 nm and 412 to 460 nm for Hoechst 33342, 405 nm and 412
to 460 nm for DAPI, 488 nm and 495 to 550 nm for Alexa488, 594 nm and 601 to 644 nm for Alexa594,
and 644 nm and 651 to 700 nm for MitoTracker Deep Red, respectively.
2.6. Cellular Proliferation, Metabolic Activity, Clonogenic Capacity
In order to determine the cell proliferation, EdU Click-iT® assay (Thermo Fisher Scientific,
Waltham, MA, USA) was used according to the manufacturer’s instructions [21]. Briefly, 4 × 105 cells
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were seeded in six-well plates in both red and white DMEM, 24 h later they were treated with E2
and ICI, and left to grow for an additional 48 h. The samples were analyzed using FACS Calibur
flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA), while acquisition was made using the
CellQuest software package (BD Biosciences, Franklin Lakes, NJ, USA). The analysis of the frequencies
of proliferative (EdU positive) cells was performed using the FCS Express 3 software package (De Novo
software, Pasadena, CA, USA). For the MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide; tetrazolium dye) assay, 5 × 103 cells were seeded in a 96-well plate and 24 h later treated
with ICI and E2 and processed as described previously in [8]. For the clonogenic capacity (CFU) assay,
2 × 103 cells were seeded in 5 cm Petri dishes, and 24 h later treated with ICI and E2. After that, the
cells were incubated for 14 days until the visible colonies were observed and processed as previously
described [8].
2.7. Migration Assay
For monitoring cell migration, 1 × 105 cells were treated for 2 h with E2 in serum-reduced DMEM,
seeded in migration Transwell Cell Culture Inserts (pore size 8 mm; Corning, Corning, NY, USA),
and left to migrate for 22 h towards 10% FBS in DMEM as a chemoattractant. Cells migrated to the
underside of the filter were fixed with 4% PFA, stained with 1% crystal violet solution, photographed,
and quantified using NIH ImageJ (v1.52a, U.S. National Institutes of Health, Bethesda, MD, USA).
2.8. Measurements of Mitochondrial Membrane Potential, Cytosolic, and Mitochondrial ROS Production
Quantitative analysis of mitochondrial membrane potential (∆Ψm), and mitochondrial superoxide
production (mtROS) was carried out using 100 nM MitoTracker Deep Red and 5 µM MitoSOX Red
reagent (both from Thermo Fisher Scientific, Waltham, MA, USA), respectively. Cytosolic ROS
production was measured with 20 µM dihydroethidium (DHE) (Invitrogen Molecular Probes, Carlsbad,
CA, USA). Sytox Red (500 nM, Thermo Fisher Scientific, Waltham, MA, USA) and PI (1.5 µg/mL)
were used for exclusion of dead cells dyed with MitoSOX Red or DHE, and MitoTracker Deep Red,
respectively. The samples were analyzed using a FACS Calibur flow cytometer as described above.
2.9. Antioxidant Enzyme Activities
Superoxide dismutase (SOD) activity was assayed with a RANSOD kit (RANDOX Labs, UK)
according to the manufacturer’s protocol. The SOD-2 activity was determined under identical
conditions with the addition of 4 mM KCN in the assay buffer for 30 min to inhibit SOD1. The SOD1
activity was obtained by subtracting the SOD2 activity from the total SOD activity. Lyophilized cells
and standard solutions were used for the SOD assay. The absorbance was measured at 505 nm on a
microplate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA).
2.10. Immunoprecipitation and Coimmunoprecipitation
Cells were seeded in white DMEM and 24 h later treated with E2 for 2 h, followed by cell lysis in
Co-IP buffer (250 mM NaCl, 0,1% NP-40, 50 mM HEPES). Since Sirt3 is FLAG-tagged, ANTI-FLAG
M2 affinity gel (Sigma-Aldrich, St. Louis, MO, USA) was used for Sirt3 coimmunoprecipitation. For
ERα, anti-ERα antibody (F-10, Santa Cruz Biotechnology, Dallas, TX, USA) was used and Pierce
Crosslink Immunoprecipitation Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the
manufacturer’s guidelines, with the exception of the Co-IP buffer instead of IP Lysis/Wash Buffer from
the kit.
2.11. Statistical Analysis
Statistical analysis of data was performed using R v2.15.3 (CRAN, http://cran.r-project.org) and
RStudio for Windows, v0.97 (http://www.rstudio.com/) and SPSS for Windows (17.0, IBM, Armonk, NY,
USA). Before all analyses, the samples were tested for normality of distribution using the Shapiro–Wilk
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test. If the data followed a non-Gaussian distribution, the following nonparametric analyses were
performed: Kruskal–Wallis non-parametric ANOVA for testing differences between groups that
do not follow normal distribution, followed by Wilcoxon signed-rank test for testing differences
between two related groups. In the case of normal distributions, the following parametric tests were
performed: two-way ANOVA, followed by Bonferroni adjustments for the analysis of (simple) main
effects. For comparisons of the two samples, the Student’s t-test or Mann–Whitney U test were used,
depending on the distribution of data. Significance was set at p < 0.05.
3. Results
3.1. Sirt3 Participates in Regulation of ERα Expression and Localization and Alters Its Response to E2
Treatment in MCF-7 Cells
To examine if and how Sirt3 affects ERα expression, first, we stably overexpressed Sirt3 in MCF-7
cells (hereafter MCF-7S3) since MCF-7 cells express Sirt3 at almost undetectable levels (Figure 1A,C
and Figure 2). Then, we analyzed mRNA and protein expression level of ERα in both MCF-7S3 and
MCF-7 cells transfected with empty plasmid as a negative control (hereafter MCF-7C) (Figure 1B,C).
Because MCF-7 cells proliferate in an E2-dependent manner [22], we next tested how E2 addition
affected its cognate receptor ERα in the absence and presence of Sirt3. We found a positive effect of Sirt3
on both esr-1 gene transcript and protein expression level, with +2.1-fold change and 30% increase in
the absence of E2, respectively (Figure 1B,C). In the absence of Sirt3, E2 addition increased ERα protein
expression (p < 0.01), whereas in Sirt3 clones it caused reduction of already upregulated ERα protein
level (p < 0.01). Antiestrogen ICI, which was added two hours prior to E2 addition, had an inhibitory
effect on ERα expression in both cell lines (Figure 1C, p < 0.001). We also examined the effects of Sirt3
or ERα silencing on ERα and Sirt3 expression (Figure 1D) and showed that Sirt3 silencing lowers the
expression of ERα (p < 0.01). Furthermore, we investigated the effect of Sirt3 on cellular localization of
ERα. Using the fractionation method, we found that E2 treatment promoted nuclear accumulation of
ERα in both cell lines (p < 0.001), whereas a lower signal observed in cells treated with ICI prior to E2
addition indicated degradation of ERα. Interestingly, Sirt3 overexpression slightly delocalizes ERα in
the cytosol (Figure 1E, p < 0.001). Confocal microscopy confirmed the primary localization of ERα in
the nucleus (Figure 2). These results collectively indicate, while E2 affects both localization and the
abundance of ERα expression, Sirt3 only affects the amount of ERα expressed in the cell.
Figure 1. Cont.
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Figure 1. Sirt3 regulates ERα expression and localization. (A) Expression of sirt-3 gene was significantly
increased in MCF-7S3 clones as compared with MCF-7C (*** p < 0.001). The results are presented as
fold change ± SE on a log-scale, normalized to the control MCF-7C. Experiments were repeated at least
three times (hereafter referred to as n ≥ 3); (B) Expression of esr-1 gene was significantly increased in the
control and E2 + ICI-treated MCF-7S3 clones as compared with MCF-7C (* p < 0.05); (C) Immunoblots
of ERα and Sirt3 protein expression level. Two-way ANOVA revealed significant interaction effect
between Sirt3 and treatment on ERα F (2,12) = 9.321, p = 0.004, partial η2 = 0.608; higher in the control
(*** p < 0.001) and E2 + ICI-treated (*** p < 0.001) MCF-7S3 vs. MCF-7C. In MCF-7C, higher in E2 vs. the
control (a p < 0.01) and E2 + ICI-treated (c p < 0.001) and in the control vs. E2 + ICI-treated (b p < 0.001).
In MCF-7S3, higher in the control vs. E2 (d p < 0.01) and E2 + ICI-treated (e p < 0.001) and in E2 vs.
E2 + ICI-treated (f p < 0.001); (D) Immunoblots of ERα and Sirt3 protein expression level in the cells
transfected with scrambled (siSCR) control or siER-α and siSirt3 RNA. Lower ERα in the siER-α-treated
vs. siSCR MCF-7C cells (a p < 0.05) and MCF-7S3 cells (b p < 0.01). In MCF-7S3, lower Sirt3 (c p < 0.05)
and ERα (d p < 0.01) in the siSirt3-treated cells; (E) Immunoblots of ERα protein expression in cellular
fractions. For cytosolic fraction, two-way ANOVA revealed a significant interaction effect between
Sirt3 and treatment F (2,12) = 54.61, p < 0.001, partial η2 = 0.948; higher cytosolic ERα in the control
MCF-7S3 vs. MCF-7C (*** p < 0.001). In MCF-7S3, higher cytosolic ERα in the control vs. E2 (a p < 0.001)
and E2 + ICI-treated group (b p < 0.001). For nuclear fraction, two-way ANOVA revealed significant
interaction effect between Sirt3 and treatment F (2,12) = 1054.57, p < 0.001, partial η2 = 0.997; higher
nuclear ERα in MCF-7S3 vs. MCF-7C (*** p < 0.001). In MCF-7C, lower nuclear ERα in the control vs.
E2 (a p < 0.001) and E2 + ICI-treated group (b p < 0.001); higher nuclear ERα in E2 vs. E2 + ICI-treated
group (c p < 0.001). In MCF-7S3, lower nuclear ERα in the control vs. E2 (d p < 0.001) and E2 +
ICI-treated group (e p < 0.001) and higher nuclear ERα in E2 vs. E2 + ICI-treated group (f p < 0.001).
For (C), (D) and (E) results are shown as a ratio of the mean ± SD normalized to the control MCF-7C
(n ≥ 3). Amidoblack was used as a loading control.
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3.2. Sirt3 Does Not Interact with ERα in MCF-7 Cells
Since the presence of ERα in mitochondria has been described by several studies [23,24], we
next investigated the possibility that ERα resides inside mitochondria and interacts with Sirt3. Using
both coimmunoprecipitation and confocal imaging, we found no interaction between ERα and Sirt3
(Supplementary Figure S1) or colocalization signal for ERα and Sirt3, respectively (Figure 2). These
results collectively suggest that Sirt3 indirectly participates in the regulation of ERα expression.
Figure 2. Sirt3 does not colocalize with ERα in MCF-7 cells. Confocal imaging of ERα localization in
control, E2, and E2 + ICI-treated MCF-7C and MCF-7S3 cells. Bar represents 10 µm.
3.3. Sirt3 Amplifies E2-Induced Metabolic Activity and Mitochondrial Fitness of MCF-7 Cells
To explore if Sirt3 plays a role in E2-induced metabolic activity of MCF-7 cells [25], we measured
several parameters of mitochondrial function. First, we tested the effect of E2 and Sirt3 on metabolic
activity of MCF-7 cells using MTT assay. The MTT salt is reduced to formazan in the metabolically
active cells predominantly by mitochondrial complex-II subunit succinate dehydrogenase A (SDH-A)
and is considered to be a marker of metabolic potential of the cell [26]. The Sirt3-overexpressing cells
had significantly higher basal metabolic activity (p < 0.001) and Sirt3 further enhanced the inducing
effect of E2 (Figure 3A), while ICI effectively abolished E2-induced metabolic activity to control levels
in both cell lines. This result was confirmed with the observed protein expression levels of SDH-A
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(Figure 3B), indicating the combined effect of E2 and Sirt3 and involvement of ERα in the regulation
of metabolic activity in MCF-7 cells. Furthermore, the expression levels of respiratory complex I
(NDUFA9) and III (UQCRC2) were also elevated in Sirt3 overexpressors (p < 0.001), although with no
significant effect of E2 (Figure 3B). Another marker of mitochondrial functionality is the mitochondrial
membrane potential (∆Ψm) which plays a key role in mitochondrial homeostasis [27]. While in
the absence of Sirt3, ∆Ψm remained unaffected by E2 or ICI addition, the MCF-7S3 cells exhibited
increased basal ∆Ψm (p = 0.003), which was further enhanced by E2 addition and abolished by ICI
(Figure 3C, p < 0.001). These results collectively suggest that (a) Sirt3 acts synergistically with E2 to
induce metabolic activity, (b) E2-induced rise in mitochondrial potential is Sirt3 dependent, and (c)
ERα is involved in Sirt3-mediated mitochondrial fitness of MCF-7 cells.
Figure 3. Sirt3 amplifies E2-induced metabolic activity and mitochondrial fitness of MCF-7 cells.
(A) Metabolic activity measured with MTT assay. Two-way ANOVA revealed significant interaction
effect between Sirt3 and treatment on metabolic activity F (2,34) = 7.051, p = 0.003, partial η2 = 0.293;
*** p < 0.001 MCF-7S3 vs. MCF-7C. In MCF-7C, higher in E2 vs. other groups (a p < 0.001). In MCF-7S3,
higher in E2-treated vs. other groups (b p < 0.001). Results are shown as mean ± SD (n ≥ 3);
(B) Immunoblots of mitochondrial respiration complexes. Two-way ANOVA revealed significant
interaction effect between Sirt3 and treatment on SDH-A expression F (2,6) = 10,846, p = 0.010, partial
η2 = 0.783; *** p < 0.001 MCF-7C vs. MCF-7S3 cells. In MCF-7C, higher SDH-A expression in E2-treated
vs. other groups (a p < 0.001). In MCF-7S3, higher SDH-A expression in E2-treated vs. other groups
(b p < 0.001). Higher UQCRC2 and NDUFA9 protein expression in MCF-7S3 cells as compared with
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MCF-7C (*** p < 0.001). Results are shown as mean ± SD normalized to the control MCF-7C
(n ≥ 3). Amidoblack was used as a loading control and representative immunoblots are shown;
(C) Mitochondrial membrane potential (∆Ψm) measured with MitoTracker Deep Red dye using flow
cytometry. Two-way ANOVA revealed significant interaction effect between Sirt3 and treatment F
(2,12) = 11,019, p = 0,010, partial η2 = 0.786; higher ∆Ψm in the control (** p = 0.003), E2, and E2 +
ICI-treated (*** p < 0.001) MCF-7S3 vs. MCF-7C. In MCF-7S3, higher ∆Ψm in E2 vs. the control and E2
+ ICI-treated (a p < 0.001). Results are shown as mean ± S.D (n ≥ 3).
3.4. Sirt3 Enhances Antioxidative Enzyme Activities and Cytosolic ROS, but Opposes E2-Induced Cytosolic
and mtROS Production
Since it is known that Sirt3 mediates mitochondrial oxidative pathways and regulates production
of ROS (reviewed by [28]), we aimed to analyze the antioxidant enzyme system in MCF-7S3 cells.
We found that MCF-7S3 cells exhibited significantly increased activities of two major antioxidative
enzymes, mitochondrial manganese-dependent superoxide dismutase MnSOD (SOD2, Figure 4A,
p < 0.001) and cytosolic copper zinc-dependent superoxide dismutase CuZnSOD (SOD1, Figure 4B,
p < 0.001), which was also confirmed by decreased expression level of inactive, acetylated form of
MnSOD, AcSOD2 (Figure 4C, p < 0.001). Moreover, protein levels of the catalase (Cat) and transcription
nuclear factor erythroid 2-related factor 2 (Nrf2), a major activator of antioxidant response, were also
upregulated in Sirt3-overexpressing cells (Figure 4C, p < 0.001). Next, we examined the role of E2
in the activation of antioxidant enzyme system. While having a positive effect on the activation of
CuZnSOD (p < 0.001), Cat (p < 0.001), and Nrf2 (p < 0.01) in the control cells, in Sirt3 overexpressors, E2
failed to further increase their already elevated levels (Figure 4B,C). Collectively, these results indicate
that Sirt3-overexpressing cells exhibit a higher antioxidative response regardless of the E2 treatment.
Due to the elevated antioxidant enzyme system in the MCF-7S3 cells, we aimed to investigate the effect
of Sirt3 and E2 on cellular ROS levels and, on the one hand, found that E2 promoted mitochondrial
ROS (mtROS) production in MCF-7C cells (p < 0.001), and this effect was inhibited by ICI (Figure 4E,
p < 0.001). On the other hand, both cytosolic and mtROS levels were significantly reduced in E2-treated
MCF-7S3 cells as compared with their controls (Figure 4D,E and p < 0.001). However, without E2
treatment, MCF-7S3 cells exhibited a significant rise in cytosolic ROS (p < 0.001) with a parallel decline
in mtROS levels (p = 0.002). These results indicate that Sirt3 increases cytosolic ROS but abolishes
E2-induced increase of both cytosolic and mtROS levels.
Figure 4. Cont.
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Figure 4. Sirt3 enhances antioxidative enzyme activities and cytosolic ROS but opposes E2-induced
cytosolic and mtROS production. (A) For MnSOD activity, two-way ANOVA revealed a significant
interaction effect between Sirt3 and treatment F(2,12) = 53,853, p < 0.001, partial η2 = 0.900; *** p < 0.001
MCF-7S3 vs. MCF-7C. In MCF-7S3, higher activity in the E2 + ICI-treated vs. the other groups
(a p < 0.001); (B) For CuZnSOD activity, two-way ANOVA revealed a significant interaction effect
between Sirt3 and treatment F (2,12) = 75,435, p < 0.001, partial η2 = 0.952; *** p < 0.001 MCF-7S3 vs.
MCF-7C. In MCF-7C, higher activity in the E2-treated vs. the other groups (a p < 0.001). In MCF-7S3,
higher activity in E2 + ICI vs. other groups (b p < 0.001). Results are shown as mean ± SD (n ≥ 3); (C) For
immunoblots of proteins of antioxidative response, two-way ANOVA revealed significant interaction
effect between Sirt3 and treatment on AcSOD2 F (2,12) = 11,691; p < 0.01, partial η2 = 0.916; E2 and E2 +
ICI-treated MCF-7S3 vs. MCF-7C (*** p < 0.001). In MCF-7S3, higher AcSOD2 in the control vs. the E2
(a p < 0.01) and E2 + ICI-treated (b p < 0.05). Two-way ANOVA revealed significant interaction effect
between Sirt3 and treatment on Cat F (2,12) = 69,293, p < 0.001, partial η2 = 0.959; *** p < 0.001 MCF-7S3
vs. MCF-7C. In MCF-7C, lower Cat in the control vs. E2 (a p < 0.001) and E2 + ICI-treated (b p < 0.01);
higher Cat in the E2 vs. E2 + ICI-treated (c p < 0.01). In MCF-7S3, lower Cat in the E2 + ICI-treated
vs. other groups (d p < 0.01). Two-way ANOVA revealed significant interaction effect between Sirt3
and treatment on Nrf2 F (2,12) = 14,011, p = 0.005, partial η2 = 0.955; the control (*** p < 0.001) and
E2-treated (** p < 0.01) MCF-7S3 vs. MCF-7C. In MCF-7C, lower Nrf2 in the control vs. the other groups
(a p < 0.01). Results are shown as mean ± SD normalized to the control MCF-7C (n ≥ 3). Amidoblack
was used as a loading control; (D) For cytosolic ROS levels measured with DHE, two-way ANOVA
revealed a significant interaction between Sirt3 and treatment F (2,12) = 805,710, p < 0.001, partial
η2 = 0.996; *** p < 0.001 MCF-7C vs. MCF-7S3 cells. In MCF-7S3, lower cytosolic ROS in E2 (a p < 0.001)
and E2 + ICI-treated (b p < 0.01) vs. the control cells; (E) For MtROS levels measured with MitoSOX Red,
two-way ANOVA revealed a significant interaction effect between Sirt3 and treatment F (2,12) = 94.860,
p < 0.001, partial η2 = 0.941; the control (** p = 0.002) and E2-treated (*** p < 0.001) MCF-7S3 vs. MCF-7C.
In MCF-7C, higher mtROS in E2-treated vs. the control (a p < 0.001); lower mtROS in E2 + ICI-treated
vs. other groups (b p < 0.001). In MCF-7S3, lower mtROS in E2-treated vs. other groups (c p < 0.01).
Results show the relative fluorescence intensity as the average geometric mean ± SD (n ≥ 3).
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3.5. Sirt3 Abolishes the Proliferative Effect of E2 on Colony Forming Capacity by Diminishing the E2-Induced
DNA Synthesis of MCF-7 Cells
Our previous results showed that Sirt3 has an inhibitory role on several tumorigenic parameters
of MCF-7 cells [8], therefore, we wanted to analyze its effect on the colony forming capacity in the
presence or absence of E2. Since the MCF-7S3 cells were not able to produce colonies in white DMEM,
we also performed this experiment in red DMEM with the addition of E2 and ICI. The observed
difference in clonogenic capacity of the cells in red and white DMEM is not surprising, since it is
well known that ERα-positive breast cancer cells grow slower in phenol red-depleted media [17].
We observed a significant decrease in the colony forming ability of the MCF-7S3 cells in red DMEM
as compared with the MCF-7C cells (Figure 5A,B and p < 0.001). As expected for the red DMEM, in
which the phenol red mimics the action of E2 and renders cells unresponsive to the proliferative effect
of physiological concentrations of E2 [29], E2 addition failed to show any difference in the number of
colonies as compared with the untreated cells. In white DMEM, the colony forming capacity of the
MCF-7C cells was reduced to 5% of their counterparts in red DMEM (Figure 5C,D). While E2 addition
potentiated the growing capacity of the MCF-7C cells to nearly 70% of the cells in red DMEM, the
MCF-7S3 cells completely failed to form colonies, even with the addition of E2. The number of colonies
treated with ICI declined in both media as compared with their corresponding controls (p < 0.001).
Collectively, these results indicate that Sirt3 attenuates the colony forming capacity of MCF-7 cells and
abolishes the proliferative effect of E2 on MCF-7 cells.
Due to the observed reduced capacity of Sirt3-overexpressing cells to divide and form colonies,
we investigated if Sirt3 affects cellular growth by inhibition of DNA synthesis using EdU Click-IT®
assay (Thermo Fisher Scientific, USA). In white DMEM, E2 significantly promoted DNA synthesis
in MCF-7C cells only (Figure 5E and p < 0.05), whereas the ICI treatment effectively inhibited DNA
synthesis in both cell lines (p < 0.05). These data collectively indicate that Sirt3 abolishes cellular
proliferation by inhibiting E2-induced DNA synthesis.
Figure 5. Cont.
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Figure 5. Sirt3 abolishes the proliferative effect of E2 on colony forming capacity by diminishing
the E2-induced DNA synthesis of MCF-7 cells. (A) Histogram showing the number of colonies in
red DMEM (CFU assay). Two-way ANOVA revealed significant interaction effect between Sirt3 and
treatment on cellular clonogenic capacity F (2,15) = 26,780; p < 0.001; partial η2 = 0.856; the control
(*** p < 0.001) and E2-treated (** p < 0.01) MCF-7S3 vs. MCF-7C. In MCF-7C, lower E2 + ICI-treated vs.
other groups (a p < 0.001). In MCF-7S3, the lower E2 + ICI-treated vs. the other groups (b p < 0.001).
Results are shown as mean ± SD (n ≥ 3); (B) Representative plates of colonies grown in red DMEM
stained with crystal violet; (C) Histogram showing the number of colonies in white DMEM (CFU assay).
Two-way ANOVA revealed a significant interaction effect between Sirt3 and treatment on cellular
clonogenic capacity F (2, 6) = 52.397, p < 0.001, partial η2 = 0.946, E2-treated (*** p < 0.001) MCF-7S3 vs.
MCF-7C. In MCF-7C, higher in the E2-treated vs. the other groups (a p < 0.001). Results are shown as
mean ± SD (n ≥ 3); (D) Representative plates of colonies grown in white DMEM stained with crystal
violet; (E) DNA synthesis as a sign of proliferation in white DMEM measured with Click-iT® assay
using flow cytometry. In MCF-7C, higher in the E2-treated vs. other groups (a p < 0.05). In MCF-7S3,
lower in the E2 + ICI-treated vs. the E2-treated group (b p < 0.05). Results are shown as mean ± SD
(n ≥ 3).
3.6. Sirt3 Induces Tumor-Suppressive Markers in MCF-7 Cells
Since in our earlier study we observed higher levels of p53 in Sirt3-overexpressing cells [8], in
this study, we investigated the level of p53 expression upon E2 treatment along with the expression
of other p53-related proteins, such as apoptosis-inducing factor (AIF) and marker of DNA double
strand breaks (phospho-γH2AX). Consistent with our previous results, the p53 level was elevated in
MCF-7S3 cells (p < 0.001). However, E2 and ICI had the opposite effect on the p53 expression level in
Sirt3-overexpressed and control cells; while both treatments decreased p53 expression in MCF-7S3
cells (p < 0.01), they elevated the expression in the control MCF-7C cells (Figure 6A, p < 0.05 for E2 and
p < 0.001 for E2 + ICI). AIF was significantly increased by both E2 and Sirt3 (p < 0.001), whereas DNA
damage showed to be higher in the presence of Sirt3 (p < 0.001), however, was lowered by E2 addition
(p < 0.001). This was confirmed by confocal microscopy which clearly demonstrated more DNA
damage in the Sirt3-overexpressed cells, and less in the E2-treated groups of both cell lines (Figure 6B).
In addition, we also noticed a higher number of micronucleated cells in the Sirt3-overexpressed line
(Figure 6C), which is considered to be an indicator of genomic instability and usually predisposes cells to
apoptosis [30]. The MCF-7S3 line displayed a higher frequency of micronucleated cells than the controls,
with values similar to the H2O2-treated cells, which were used as a positive control for the induction
of apoptosis [31]. Since earlier studies showed that upon both DNA damage and p53 activation, cell
migration is decreased [32–34], we also checked the migration of the cells. The migration rate was
reduced in the MCF-7S3 cells as compared with the controls (p = 0.007). Moreover, while migration
was not affected by E2 in the control cells, E2 administration only slightly increased migration in the
Sirt3 overexpressors (Figure 6D and Supplementary Figure S2). These data collectively demonstrate
the tumor-suppressive role of Sirt3 in MCF-7 cells, which is partially restored by E2 treatment.
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Figure 6. Sirt3 induces tumor-suppressive markers in MCF-7 cells. (A) Western blot analysis of proteins
associated with tumor-suppressive function. Two-way ANOVA revealed a significant interaction effect
between Sirt3 and treatment on the p53 level F (2,12) = 118.1, p < 0.001, partial η2 = 0.975; higher in the
MCF-7S3 control and E2-treated (*** p < 0.001) and E2 + ICI-treated (** p < 0.01) vs. MCF-7C. In MCF-7C,
higher in the E2 (a p < 0.05) and E2 + ICI-treated (b p < 0.001) vs. the control. In MCF-7S3, lower in the
E2 and E2 + ICI-treated vs. the control (c,d p < 0.01). For AIF, two-way ANOVA revealed a significant
interaction effect between Sirt3 and treatment F (2,12) = 187.56, p < 0.001, partial η2 = 0.984; *** p < 0.001
MCF-7S3 vs. MCF-7C. In MCF-7C, higher in the E2 and E2 + ICI-treated vs. the control (a,b p < 0.001).
In MCF-7S3, higher in the E2 and E2 + ICI-treated vs. the control (c,d p < 0.001). For phospho-γH2AX,
two-way ANOVA revealed significant interaction effect between Sirt3 and treatment F (2,12) = 5.39,
p < 0.05, partial η2 = 0.642; the MCF-7S3 control (*** p < 0.001), E2 (** p < 0.01), and E2 + ICI-treated
(* p < 0.05) vs. MCF-7C. In MCF-7C, lower in E2 vs. the control (a p < 0.05) and E2 + ICI-treated
(b p < 0.01). In MCF-7S3, lower in E2 vs. the control (c p < 0.001) and E2 + ICI-treated (d p < 0.01). Results
are shown as mean ± SD (n ≥ 3). Amidoblack was used as a loading control; (B) Confocal imaging of
phospho-γH2AX signal abundance as a marker of DNA damage in MCF-7C and MCF-7S3 cells with or
without E2 treatment. Bar represents 10 µm; (C) Graphical chart of frequency of micronucleated cells in
MCF-7C and MCF-7S3 cells, as well as in MCF-7C cells treated with H2O2 as a positive control. The
experiments were repeated at least three times and representative data are shown; (D) Graphical chart
of number of migrated MCF-7C and MCF-7S3 cells with or without E2 treatment. Two-way ANOVA
revealed a significant effect of Sirt3 on migration rate F (1,23) = 1.812, p = 0.007, partial η2 = 0.279; lower
in MCF-7S3 vs. MCF-7C cells (** p = 0.007). Results are shown as mean ± SD (n ≥ 3).
3.7. Sirt3 Induces Disruption of ERα–p53 Interaction in MCF-7 Cells
Due to the observed higher expression of p53 in MCF-7S3 cells, we hypothesized that Sirt3 can
contribute to the lower proliferative capacity of the cells by increasing the p53 level. It is known that
ERα binds p53 and represses its function [35]. Since we observed no interaction between Sirt3 and
p53 (Supplementary Figure S1), we tested to determine if Sirt3 affects p53 indirectly by altering the
crosstalk between ERα and p53. Using coimmunoprecipitation, we demonstrated that in the MCF-7S3
cells ERα binding to p53 was markedly reduced as compared with the MCF-7C cells (p < 0.001) and
E2 addition partially reverted this interaction (Figure 7). These results indicate that Sirt3-induced
disruption of the ERα–p53 interaction is partially reverted by E2 addition.
Collectively, on the one hand, the results show that Sirt3 improved the antioxidative response and
mitochondrial fitness of the MCF-7 cells. On the other hand, it increased cytosolic ROS, DNA damage,
along with p53, AIF, and ERα expression. Moreover, Sirt3 disrupted the p53–ERα interaction resulting
in attenuation of tumor-promoting properties and proliferative effect of E2 in MCF-7 cells.
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Figure 7. Sirt3 induces disruption of the ERα–p53 interaction in MCF-7 cells. Western blot analysis of
coimmunoprecipitation experiment of ERα and its interacting partners using anti-ERα and anti-p53
antibody. For input p53, MCF-7C + E2 vs. MCF-7C (a p < 0.001), MCF-7S3 + E2 vs. MCF-7S3 (b p < 0.01),
the MCF-7S3 control vs. MCF-7C (*** p < 0.001), MCF-7S3 + E2 vs. MCF-7C (** p < 0.01). For input
ERα, MCF-7C + E2 vs. MCF-7C (a p < 0.01), MCF-7S3 vs. MCF-7C (*** p < 0.001). For IP-ERα, a control
that IP was successful (MCF-7C + E2 vs. MCF-7C a p < 0.001, MCF-7S3 + E2 vs. MCF-7S3 b p < 0.001,
and MCF-7S3 vs. MCF-7C (*** p < 0.001). For IP-Sirt3, a confirmation that there is no interaction
between ERα and Sirt3. For IP-p53, two-way ANOVA revealed a significant interaction effect between
Sirt3 and treatment on the p53 level F (1,4) = 64.47, p = 0.001, partial η2 = 0.942; lower in the control
(*** p < 0.001) and the E2-treated (** p < 0.01) MCF-7S3 vs. MCF-7C. In MCF-7S3, lower in the control
vs. the E2-treated cells (c p = 0.003). Representative blots are shown (n ≥ 3).
4. Discussion
The significance of Sirt3 in breast cancer cells lies in the fact that only 23% of normal breast
tissue shows to be negative for Sirt3 expression, whereas even up to 72% of in situ breast lesions
and 74% of invasive lesions are negative for the expression of Sirt3 [14]. Previously, we showed
the tumor-suppressive role of overexpressed Sirt3 in human MCF-7 breast cancer cells, which are
characterized by low Sirt3 expression [8]. In this study, we investigated if the tumor-suppressive effect
of Sirt3 is mediated through the ERα signaling pathway in MCF-7 cells [3]. In this study, we report that
a mitochondrial protein Sirt3, despite improving the mitochondrial function, induces DNA damage
and tumor-suppressive factors, affects p53 by disruption of the ERα–p53 interaction, reduces response
of the MCF-7 cells to E2 treatment, and consequently inhibits the migration and clonogenic capacity of
the cells.
The expression of ERα can be regulated by different cellular factors and mechanisms (reviewed
by [36]) and, in our study, we found that there is significant upregulation of ERα expression in
Sirt3-overexpressing cells (Figure 1B,C). Furthermore, Sirt3 silencing caused downregulation of ERα
expression (Figure 1D), indicating the involvement of Sirt3 in the ERα expression level. Since Sirt3 is a
mitochondrial protein and ERα is mostly localized in the nucleus [37,38], it is unlikely that they interact.
Some earlier studies proposed the regulation of a small fraction of ERα by estrogen in mitochondria
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(reviewed by [39]), but these claims are still controversial. We were also not able to confirm interaction
between Sirt3 and ERα (Supplementary Figure S1). Moreover, confocal microscopy confirmed, in our
model, that ERα, indeed, does not reside inside mitochondria, and Sirt3 does not reside in the nucleus
(Figure 2) or cytoplasm, as was already shown in our previous study [8]. Thus, we hypothesized that
overexpressed Sirt3 indirectly regulates the expression of ERα in MCF-7 breast cancer cells. It is known
that ERα contains a nuclear localization signal for the transport into the nucleus, which happens 10
to 30 min after E2 stimulation (reviewed by [40]). Therefore, we investigated the nuclear level of
ERα as an indicator of its E2-stimulated activation. The fractionation experiments indicated that both
MCF-7C and MCF-7S3 cells have functional ERα because it was successfully shuttled into the nucleus
upon E2 treatment (Figure 1E). ICI, a compound that impairs the dimerization of ER-α, an event that
takes place after E2 binding and is essential for the nuclear localization of the receptor [41], led to
receptor degradation (Figure 1C,E) and partially depleted its nuclear localization as judged by more
cytoplasmic ERα (Figure 2). Altogether, these data confirmed that ERα in our system is activated by
E2 and that ICI is a good control for analysis of the ER-dependent pathways.
Several studies have shown that E2 has the ability to increase mitochondrial function and
biogenesis (reviewed in [42]), therefore, we explored whethe Sirt3 plays a role in E2-induced metabolic
fitness of MCF-7 cells. As observed in Figure 3A,C, Sirt3 potentiated this inducing effect of E2
leading to increased metabolic activity, primarily as a result of the induced rise in SDH-A expression
(Figure 3B) [26]. This is not surprising, considering that ERα is an essential estrogen receptor for most
E2-mediated increases in respiratory chain proteins and antioxidant enzymes [43,44]. Furthermore,
Sirt3 also induced expression of complex I (NDUFA9) and III (UQCRC2) and elevated mitochondrial
potential (Figure 3C). The latter was further enhanced upon E2 addition, indicating that the E2-induced
rise in mitochondrial potential is Sirt3 dependent.
Elevated ROS is a common hallmark of cancer progression and can activate oncogenic signals
involved in cell proliferation [45,46], hence, we wanted to check the ROS status of our cell lines.
In agreement with others [47], our results showed that E2 promoted mtROS production in MCF-7C
cells, while ICI abolished this effect (Figure 4E), suggesting the involvement of the ERα receptor in the
E2-induced production of mtROS. This is not surprising, since E2 plays a critical role in the development
of breast cancer by altering the mitochondrial function and causing a shift towards higher mtROS
levels [48]. Sirt3 is a mitochondrial protein involved in the regulation of mitochondrial oxidative
pathways [28] and we tested to determine if it regulates E2-induced proliferation by affecting ROS
levels. In Sirt3-overexpressing cells, we observed lower mtROS levels (Figure 4E) and hypothesized
that this could be the result of a more efficient mitochondrial antioxidant enzyme system induced
by Sirt3. The oxidative stress response is manifested through upregulated antioxidative enzymes
such as SOD and Cat that are under the control of Nrf2, which is activated upon oxidative stress or
increased ROS production (reviewed by [49]). Our results showed a significant increase of Nrf2, Cat,
and SOD in the MCF-7S3 cells (Figure 4A–C), indicating that the Sirt3-induced antioxidative response
is associated with enhanced metabolic activity of the cells. Contrary to the MCF-7C cells, the E2-treated
Sirt3-overexpressed cells showed lowered levels of both cytosolic and mtROS (Figure 4D,E), suggesting
that the E2-generation of ROS is attenuated by Sirt3. Since numerous data postulate that an increase in
ROS generated after exposure to E2 contributes to the development of human breast cancer [50,51], our
findings propose that Sirt3 can function as a tumor suppressor by activating antioxidative enzymes
and attenuating the E2-induced ROS levels from both cytosolic and mitochondrial compartments.
Although the Sirt3-overexpressing cells demonstrated improved mitochondrial function and
antioxidative enzyme system response, the opposite effect was observed on their proliferation and
migration. Control of proliferation by estrogens is a very complex process based on E2 binding to ERα
and subsequent regulation of target genes and concomitant activation of G1 to S phase progression [16].
In the case of non-invasive ERα-positive MCF-7 cells that otherwise display reduced expression of
Sirt3 protein [52], the overexpression of Sirt3 diminished their growth, suggesting that Sirt3 inhibits
their tumorigenic properties [8]. Furthermore, this inhibitory effect of Sirt3 is enhanced in the white
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DMEM regardless of E2 treatment (Figure 5A–D), indicating again that Sirt3 attenuates the proliferative
effect of E2 on these cells. Interestingly, the observation that Sirt3-overexpressing cells have higher
metabolic activity (Figure 3A) seems opposite to the fact that they show lower proliferation (Figure 5).
However, cell cycle arrest does not necessarily result in metabolic dysfunction. On the contrary,
some stressors can even increase the metabolic activity [53]. The Sirt3-mediated inhibitory effect on
E2-induced proliferation was also supported by the analysis of DNA synthesis where we showed that
E2 promotes DNA synthesis to a lesser extent in the MCF-7S3 cells as compared with the MCF-7C cells
(Figure 5E). ICI decreases BrdU incorporation irrespective of Sirt3, confirming previous findings of the
anti-proliferative effect of ICI by inhibition of DNA synthesis [53].
The mechanism of the Sirt3 effect on the reduction of clonogenic capacity is still not clear but
involves DNA damage accumulation observed as an increase inγH2AX phosphorylation. The increased
DNA damage was accompanied by a higher frequency of micronucleated cells in Sirt3-overexpressed
cells, which are characterized by small, extra-nuclear chromatin bodies that arise in dividing cells
due to chromosome aberrations or genome mutations (reviewed by [30]), and therefore are used
as an indicator of genomic instability. In addition to the observed higher DNA damage and more
micronucleated cells, the Sirt3-overexpressed cells also showed lower migration capacity. Some of
these effects were partially rescued by E2 addition (Figure 6 and Supplementary Figure S2). These
observations indicate that Sirt3 overexpression is associated with excessive genomic instability of
MCF-7 cells, which can be alleviated by E2 treatment but only to a limited extent. However, this is not
sufficient to rescue tumorigenic properties of these cells.
Since, in our earlier study, we observed higher levels of p53 in MCF-7S3 cells [8], we hypothesized
that Sirt3 contributes to lower cellular proliferative capacity by increasing the p53 level. The upregulation
of p53 and the tumor-suppressive effect of Sirt3 was shown also in other types of cancers [54,55]. The p53
protein is a transcriptional regulator and tumor suppressor that activates target genes for cell cycle arrest,
apoptosis, and DNA repair, and is stabilized within the nucleus upon DNA damage or oncogenic signals
(reviewed by [56]). Furthermore, p53 balances mitochondrial respiration by inhibiting the glycolysis
and promoting OXPHOS. Our results showed that p53 is indeed upregulated in Sirt3-overexpressing
cells (Figure 6A), but not through the interaction between Sirt3 and p53 (Supplementary Figure S1).
Consistently, the apoptosis inducing factor (AIF), known to be transcriptionally upregulated by p53 [57],
was also upregulated in Sirt3 clones. AIF is a mitochondrial flavoprotein harboring numerous functions
for efficient oxidative phosphorylation and cytoprotective role in the mitochondria [58,59]. However,
it has the opposite effect on cell survival upon translocation to the nucleus, where it serves as a potent
pro-apoptotic trigger [60], resulting in large-scale DNA fragmentation [61]. This is also in line with the
observed higher frequency of micronucleated cells in Sirt3-overexpressing cells (Figure 6C). Studies
have shown that ERα directly binds to p53 and represses its function, thus, affecting p53-mediated cell
cycle arrest [62]. Since ERα binding to p53 results in inactivation of p53, disruption of this interaction
by Sirt3 indicates the possible mechanism of the tumor suppressive role of Sirt3 in breast cancer. Our
results suggest that this disruption of the ERα–p53 interaction is partially rescued upon E2 addition
(Figure 7). However, these E2-mediated effects are not sufficient for MCF-7S3 cells to reach the
proliferation capacity of the control cells (Figure 5A–D). Furthermore, the observed overexpression of
ERα (Figure 1C) correlates well with the increased level of p53 (Figure 6A), which is associated with
inhibition of cellular growth [63]. Finally, while p53 can enhance metabolic activity by promoting
OXPHOS [56], at the same time it inhibits cell cycle progression and causes a suppressive effect on
growth of cancer cells.
5. Conclusions
In conclusion, based on the results from this study, we report that Sirt3, despite improving the
mitochondrial function of MCF-7 breast cancer cells, reduces their response to E2, affects p53 by
disruption of the ERα–p53 interaction, and inhibits clonogenic cell growth. Furthermore, the tumor
suppressive effects of Sirt3 could be partially reversed by E2 treatment, but this is not sufficient to
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rescue the full tumorigenic potential of these cells. Therefore, because the majority of breast cancers
are negative for the expression of Sirt3, we conclude that by reverting its expression in MCF-7 cells,
breast cancer cell normalization could be induced. Thus, Sirt3 should be considered to be a potential
therapeutic measure for treating E2-dependent breast cancers.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3921/9/4/294/s1,
Table S1: Antibodies used in this study for Western blot analyses, Table S2: Antibodies used in this study for
immunofluorescence analyses, Figure S1: Sirt3 does not interact with p53 or ERα in MCF-7 cells, Figure S2: E2
partially rescues reduced migration of MCF-7S3 cells.
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